Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 39
Filter
1.
Antimicrob Agents Chemother ; 52(3): 1040-5, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18180357

ABSTRACT

In Papua, Indonesia, the antimalarial susceptibility of Plasmodium vivax (n = 216) and P. falciparum (n = 277) was assessed using a modified schizont maturation assay for chloroquine, amodiaquine, artesunate, lumefantrine, mefloquine, and piperaquine. The most effective antimalarial against P. vivax and P. falciparum was artesunate, with geometric mean 50% inhibitory concentrations (IC50s) (95% confidence intervals [CI]) of 1.31 nM (1.07 to 1.59) and 0.64 nM (0.53 to 0.79), respectively. In contrast, the geometric mean chloroquine IC50 for P. vivax was 295 nM (227 to 384) compared to only 47.4 nM (42.2 to 53.3) for P. falciparum. Two factors were found to significantly influence the in vitro drug response of P. vivax: the initial stage of the parasite and the duration of the assay. Isolates of P. vivax initially at the trophozoite stage had significantly higher chloroquine IC50s (478 nM [95% CI, 316 to 722]) than those initially at the ring stage (84.7 nM [95% CI, 45.7 to 157]; P < 0.001). Synchronous isolates of P. vivax and P. falciparum which reached the target of 40% schizonts in the control wells within 30 h had significantly higher geometric mean chloroquine IC50s (435 nM [95% CI, 169 to 1,118] and 55.9 nM [95% CI, 48 to 64.9], respectively) than isolates that took more than 30 h (39.9 nM [14.6 to 110.4] and 36.9 nM [31.2 to 43.7]; P < 0.005). The results demonstrate the marked stage-specific activity of chloroquine with P. vivax and suggest that susceptibility to chloroquine may be associated with variable growth rates. These findings have important implications for the phenotypic and downstream genetic characterization of P. vivax.


Subject(s)
Antimalarials/pharmacology , Plasmodium vivax/drug effects , Plasmodium vivax/growth & development , Animals , Chloroquine/pharmacology , Humans , Inhibitory Concentration 50 , Life Cycle Stages/drug effects , Parasitic Sensitivity Tests/methods , Plasmodium falciparum/drug effects , Schizonts/drug effects , Schizonts/growth & development , Time Factors
2.
Trop Med Int Health ; 12(2): 251-9, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17300633

ABSTRACT

OBJECTIVES: To compare the efficacy and tolerability of dihydroartemisinin-piperaquine (DHA-PQP) with that of a 3-day regimen of mefloquine and artesunate (MAS3) for the treatment of uncomplicated falciparum malaria in Cambodia. METHOD: Randomized open-label non-inferiority study over 64 days. RESULTS: Four hundred and sixty-four patients were included in the study. The polymerase chain reaction genotyping-adjusted cure rates on day 63 were 97.5% (95% confidence interval, CI, 93.8-99.3) for DHA-PQP and 97.5% (95% CI, 93.8-99.3) for MAS3, P = 1. There were no serious adverse events, but significantly more episodes of vomiting (P = 0.03), dizziness (P = 0.002), palpitations (P = 0.04), and sleep disorders (P = 0.03) reported in the MAS3 treatment group, consistent with the side-effect profile of mefloquine. CONCLUSIONS: DHA-PQP was as efficacious as MAS3, but much better tolerated, making it more appropriate for use in a routine programme setting. This highly efficacious, safe and more affordable fixed-dose combination could become the treatment of choice for Plasmodium falciparum malaria in Cambodia.


Subject(s)
Antimalarials/therapeutic use , Artemisinins/therapeutic use , Malaria, Falciparum/drug therapy , Quinolines/therapeutic use , Sesquiterpenes/therapeutic use , Adolescent , Adult , Aged , Anemia/complications , Anemia/epidemiology , Antimalarials/adverse effects , Artemisinins/adverse effects , Artesunate , Cambodia/epidemiology , Child , Child, Preschool , Drug Therapy, Combination , Female , Genome, Protozoan , Humans , Infant , Malaria, Falciparum/epidemiology , Malaria, Falciparum/parasitology , Malaria, Vivax/drug therapy , Malaria, Vivax/epidemiology , Malaria, Vivax/parasitology , Male , Mefloquine/therapeutic use , Middle Aged , Quinolines/adverse effects , Recurrence , Sesquiterpenes/adverse effects , Treatment Outcome
3.
Trans R Soc Trop Med Hyg ; 101(4): 351-9, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17028048

ABSTRACT

To determine the level of antimalarial drug resistance in southern Papua, Indonesia, we assessed the therapeutic efficacy of chloroquine plus sulfadoxine-pyrimethamine (CQ+SP) for Plasmodium falciparum infections as well as CQ monotherapy for P. vivax infections. Patients with P. falciparum failing therapy were re-treated with unsupervised quinine+/-doxycycline therapy and those with P. vivax with either unsupervised quinine+/-doxycycline or amodiaquine. In total, 143 patients were enrolled in the study (103 treated with CQ+SP and 40 with CQ). Early treatment failures occurred in four patients (4%) with P. falciparum and six patients (15%) with P. vivax. The failure rate by Day 28 for P. vivax was 65% (95% CI 49-81). After PCR correction for re-infections, the Day 42 recrudescence rate for P. falciparum infections was 48% (95% CI 31-65). Re-treatment with unsupervised quinine+/-doxycycline resulted in further recurrence of malaria in 48% (95% CI 31-65) of P. falciparum infections and 70% (95% CI 37-100) of P. vivax infections. Eleven patients with recurrent P. vivax were re-treated with amodiaquine; there were no early or late treatment failures. In southern Papua, a high prevalence of drug resistance of P. falciparum and P. vivax exists both to first- and second-line therapies. Preliminary data indicate that amodiaquine retains superior efficacy compared with CQ for CQ-resistant P. vivax.


Subject(s)
Antimalarials/therapeutic use , Drug Resistance, Multiple , Malaria, Falciparum/drug therapy , Malaria, Vivax/drug therapy , Adolescent , Adult , Aged , Aged, 80 and over , Animals , Antimalarials/adverse effects , Antimalarials/blood , Child , Child, Preschool , Chloroquine/adverse effects , Chloroquine/blood , Chloroquine/therapeutic use , Drug Combinations , Drug Therapy, Combination , Female , Humans , Infant , Malaria, Falciparum/blood , Malaria, Vivax/blood , Male , Middle Aged , Plasmodium falciparum/drug effects , Plasmodium vivax/drug effects , Prospective Studies , Pyrimethamine/adverse effects , Pyrimethamine/therapeutic use , Recurrence , Sulfadoxine/adverse effects , Sulfadoxine/therapeutic use , Treatment Failure , Treatment Outcome
4.
Am J Trop Med Hyg ; 69(1): 42-4, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12932095

ABSTRACT

To evaluate the effect of long-term storage of sample filters on the sensitivity of polymerase chain reaction (PCR) detection of malaria, 252 blood spots from patients with microscopically confirmed Plasmodium falciparum malaria were analyzed and stratified by storage duration. The spots were collected between 1996 and 2000 on filter paper and stored at room temperature. A Chelex-based method was used to extract the DNA. Unexpectedly, after the first purification, the sensitivity of the PCR from recently stored samples was low and showed progressively increased with time storage (P = 0.003, by chi-square test for linear trend). This suggested that PCR inhibitors were easier to dissolve from the more recent blood spots (< 4 years old) than from blood spots > or = 4 years old, thus leading to a time-dependent increase in PCR sensitivity. However, if DNA was purified again (when the first PCR result was negative), the cumulative sensitivity was not influenced by storage duration. This indicated that length of storage is not a critical issue providing purification is sufficient.


Subject(s)
DNA, Protozoan/blood , Malaria, Falciparum/diagnosis , Plasmodium falciparum/isolation & purification , Polymerase Chain Reaction/methods , Reagent Strips , Specimen Handling/methods , Animals , Child , Humans , Malaria, Falciparum/blood , Malaria, Falciparum/parasitology , Micropore Filters , Plasmodium falciparum/genetics , Sensitivity and Specificity , Time Factors
6.
Ann Trop Med Parasitol ; 96(6): 553-7, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12396318

ABSTRACT

To assess the local efficacy of chloroquine for the treatment of acute, uncomplicated, Plasmodium falciparum malaria, children and adults from Sekong province (an area of Laos with a low intensity of transmission) were tested in a 28-day, in-vivo study. Complete data were collected from 88 of the 102 subjects enrolled between October 1999 and September 2000. After genotypic analysis to distinguish recrudescing infections from re-infections, 35 (39.7%, with a 95% confidence interval of 29.5%-50.7%) of these 88 patients were considered treatment failures. These results seriously question the use of chloroquine as the first-line treatment for P. falciparum malaria in the study area.


Subject(s)
Antimalarials/therapeutic use , Chloroquine/therapeutic use , Malaria, Falciparum/drug therapy , Acute Disease , Adolescent , Adult , Animals , Child , Child, Preschool , Female , Genotype , Humans , Infant , Laos , Male , Middle Aged , Plasmodium falciparum/genetics , Quality Control , Recurrence , Treatment Failure , Treatment Outcome
7.
Trans R Soc Trop Med Hyg ; 95(6): 651-6, 2001.
Article in English | MEDLINE | ID: mdl-11816439

ABSTRACT

In areas where multidrug-resistant Plasmodium falciparum (MDR-Pf) is prevalent, only quinine is known to be safe and effective in pregnant women. On the western border of Thailand, 7 days of supervised quinine (30 mg/kg daily) cures two-thirds of P. falciparum-infected women in the 2nd and 3rd trimesters of pregnancy. Artesunate is effective against MDR-Pf and the limited data on its use in pregnancy suggest it is safe. An open randomized comparison of supervised quinine (10 mg salt/kg every 8 h) in combination with clindamycin (5 mg/kg every 8 h) for 7 days (QC7) versus artesunate 2 mg/kg per day for 7 days (A7) was conducted in 1997-2000 in 129 Karen women with acute uncomplicated falciparum malaria in the 2nd or 3rd trimesters of pregnancy. There was no difference in the day-42 cure rates between the QC7 (n = 65) and A7 (n = 64) regimens with an efficacy of 100% in both, confirmed by parasite genotyping. The A7 regimen was also associated with less gametocyte carriage; the average person-gametocyte-weeks for A7 was 3 (95% CI 0-19) and for QC7 was 39 (95% CI 21-66) per 1000 person-weeks, respectively (P < 0.01). There was no difference in gastrointestinal symptoms between the groups but there was significantly more tinnitus in the QC7 group compared to the A7 group (44.9% vs 8.9%; RR 5.1; 95% CI 1.9-13.5; P < 0.001). The favourable results with quinine-clindamycin mean that there is a useful back-up treatment for women with falciparum malaria who experience quinine and artesunate failures in pregnancy. Adherence to the 7-day regimen and cost (US$18.50 per treatment) are likely to be the main obstacles to this regimen.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Antimalarials/administration & dosage , Artemisinins , Clindamycin/administration & dosage , Malaria, Falciparum/drug therapy , Pregnancy Complications, Parasitic/drug therapy , Quinine/administration & dosage , Sesquiterpenes/administration & dosage , Adolescent , Adult , Anti-Bacterial Agents/adverse effects , Antimalarials/adverse effects , Artesunate , Clindamycin/adverse effects , Drug Combinations , Drug Resistance, Multiple , Female , Humans , Pregnancy , Pregnancy Outcome , Quinine/adverse effects , Sesquiterpenes/adverse effects , Treatment Outcome
8.
Lancet ; 356(9226): 297-302, 2000 Jul 22.
Article in English | MEDLINE | ID: mdl-11071185

ABSTRACT

BACKGROUND: Worsening drug resistance in Plasmodium falciparum malaria is a major threat to health in tropical countries. We did a prospective study of malaria incidence and treatment in an area of highly multidrug-resistant P. falciparum malaria. METHODS: We assessed incidence of P. falciparum malaria and the in-vivo responses to mefloquine treatment over 13 years in two large camps for displaced Karen people on the northwest border of Thailand. During this time, the standard mefloquine dose was first increased, and then combined artesunate and mefloquine was introduced as first-line treatment for uncomplicated P. falciparum malaria. FINDINGS: Early detection and treatment controlled P. falciparum malaria initially while mefloquine was effective (cure rate with mefloquine [15 mg/kg] and sulphadoxine-pyrimethamine in 1985, 98% [95% CI 97-100]), but as mefloquine resistance developed, the cure rate fell (71% [67-77] in 1990). A similar pattern was seen for high-dose (25 mg/kg) mefloquine monotherapy from 1990-94. Since the general deployment of the artesunate-mefloquine combination in 1994, the cure rate increased again to almost 100% from 1998 onwards, and there has been a sustained decline in the incidence of P. falciparum malaria in the study area. In-vitro susceptibility of P. falciparum to mefloquine has improved significantly (p=0.003). INTERPRETATION: In this area of low malaria transmission, early diagnosis and treatment with combined artesunate and mefloquine has reduced the incidence of P. falciparum malaria and halted the progression of mefloquine resistance. We recommend that antimalarial drugs should be combined with artemisinin or a derivative to protect them against resistance.


Subject(s)
Antimalarials/therapeutic use , Artemisinins , Malaria, Falciparum/drug therapy , Malaria, Falciparum/epidemiology , Mefloquine/administration & dosage , Sesquiterpenes/administration & dosage , Animals , Antimalarials/administration & dosage , Artesunate , Cohort Studies , Drug Resistance, Multiple , Drug Therapy, Combination , Female , Humans , Incidence , Male , Mefloquine/therapeutic use , Plasmodium falciparum/drug effects , Pregnancy , Pregnancy Complications, Parasitic/drug therapy , Pregnancy Complications, Parasitic/epidemiology , Prospective Studies , Random Allocation , Sesquiterpenes/therapeutic use , Thailand/epidemiology
9.
Rapid Commun Mass Spectrom ; 14(21): 2034-8, 2000.
Article in English | MEDLINE | ID: mdl-11085415

ABSTRACT

The need for increased throughput in the quantitation of target compounds in biological fluids by high performance liquid chromatography/mass spectrometry continues to drive research in this area. This report describes the application of a prototype dual sprayer electrospray source for the quantitative analysis of biological samples. Quantitative performance for 180 compounds in a microsomal stability assay was found to be adequate when compared with a conventional single sprayer measurement. Issues with use of dual sprayers in a routine production environment are discussed.


Subject(s)
Spectrometry, Mass, Electrospray Ionization/instrumentation , Spectrometry, Mass, Electrospray Ionization/methods , Animals , Biological Factors/analysis , Biological Factors/chemistry , Biological Factors/metabolism , Chromatography, High Pressure Liquid/instrumentation , Chromatography, High Pressure Liquid/methods , Half-Life , Microsomes, Liver/chemistry , Microsomes, Liver/metabolism
10.
Mol Biol Evol ; 17(10): 1467-82, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11018154

ABSTRACT

Multilocus genotyping of microbial pathogens has revealed a range of population structures, with some bacteria showing extensive recombination and others showing almost complete clonality. The population structure of the protozoan parasite Plasmodium falciparum has been harder to evaluate, since most studies have used a limited number of antigen-encoding loci that are known to be under strong selection. We describe length variation at 12 microsatellite loci in 465 infections collected from 9 locations worldwide. These data reveal dramatic differences in parasite population structure in different locations. Strong linkage disequilibrium (LD) was observed in six of nine populations. Significant LD occurred in all locations with prevalence <1% and in only two of five of the populations from regions with higher transmission intensities. Where present, LD results largely from the presence of identical multilocus genotypes within populations, suggesting high levels of self-fertilization in populations with low levels of transmission. We also observed dramatic variation in diversity and geographical differentiation in different regions. Mean heterozygosities in South American countries (0.3-0.4) were less than half those observed in African locations (0. 76-0.8), with intermediate heterozygosities in the Southeast Asia/Pacific samples (0.51-0.65). Furthermore, variation was distributed among locations in South America (F:(ST) = 0.364) and within locations in Africa (F:(ST) = 0.007). The intraspecific patterns of diversity and genetic differentiation observed in P. falciparum are strikingly similar to those seen in interspecific comparisons of plants and animals with differing levels of outcrossing, suggesting that similar processes may be involved. The differences observed may also reflect the recent colonization of non-African populations from an African source, and the relative influences of epidemiology and population history are difficult to disentangle. These data reveal a range of population structures within a single pathogen species and suggest intimate links between patterns of epidemiology and genetic structure in this organism.


Subject(s)
Evolution, Molecular , Gene Frequency , Malaria, Falciparum/epidemiology , Microsatellite Repeats , Plasmodium falciparum/genetics , Africa/epidemiology , Animals , Biological Evolution , Genetic Variation , Genotype , Geography , Humans , Linkage Disequilibrium , Papua New Guinea/epidemiology , Plasmodium falciparum/classification , Probability , South America
11.
Trans R Soc Trop Med Hyg ; 94(6): 689-93, 2000.
Article in English | MEDLINE | ID: mdl-11198658

ABSTRACT

Since no effective malaria prevention measures have been identified for pregnant women living on the western border of Thailand, prompt diagnosis and efficient treatment are paramount, although drug resistance in Plasmodium falciparum has narrowed the treatment options. An open randomized comparison of supervised quinine (10 mg salt/kg every 8 h) for 7 days (Q7) versus mefloquine 25 mg base/kg (total dose) plus artesunate 4 mg/kg per day for 3 days (MAS3) was conducted in 1995-97 in 108 Karen women with acute uncomplicated falciparum malaria in the second or third trimesters of pregnancy. The MAS3 regimen was more effective than the Q7 regimen: day 63 cure rates were 98.2% (95% CI 94.7-100) (n = 65) for MAS3 and 67.0% (95% CI 43x3-90x8) (n = 41) for Q7, P = 0x001. The MAS3 regimen was also associated with less gametocyte carriage; the average person-gametocyte-weeks for MAS3 was 2.3 (95% CI 0-11) and for Q7 was 46x9 (95% CI 26-78) per 1000 person-weeks, respectively (P < 0.001). MAS3 was significantly better tolerated. These evident advantages must be balanced against a possible increased risk of stillbirth with the use of mefloquine in pregnancy. Further randomized studies assessing the safety and efficacy of other artemisinin-containing combination regimens in pregnancy are needed urgently.


Subject(s)
Antimalarials/therapeutic use , Artemisinins , Malaria, Falciparum/drug therapy , Mefloquine/therapeutic use , Pregnancy Complications, Parasitic/drug therapy , Sesquiterpenes/therapeutic use , Adolescent , Adult , Artesunate , Drug Resistance, Multiple , Drug Therapy, Combination , Female , Follow-Up Studies , Humans , Pregnancy , Recurrence
12.
Trans R Soc Trop Med Hyg ; 94(5): 545-8, 2000.
Article in English | MEDLINE | ID: mdl-11132386

ABSTRACT

The efficacy and safety of the 6-dose regimen of artemether-lumefantrine were assessed in an open randomized trial in children and adults presenting with acute, uncomplicated Plasmodium falciparum malaria in Thailand between November 1997 and March 1998. 200 patients were enrolled in 2 centres: 150 received artemether-lumefantrine (i.e., a median total dose of 9.6 mg/kg [interquartile range 8.7-10.7] and 57.9 mg/kg of lumefantrine [52.4-64.0]) and 50 the standard combination of artesunate (12 mg/kg over 3 d) and mefloquine (25 mg/kg). All patients had rapid initial clinical and parasitological responses. The 28 d cure rates were high: 97.7% (95% confidence interval [95% CI] 93.5-99.5%) for artemether-lumefantrine and 100% (95% CI 92.5-100%) for artesunate-mefloquine. The 6-dose regimen of artemether-lumefantrine was better tolerated than, and as effective as, artesunate-mefloquine, the current standard treatment in this area of multidrug-resistant P. falciparum malaria.


Subject(s)
Antimalarials/therapeutic use , Artemisinins , Drug Resistance, Multiple , Ethanolamines/therapeutic use , Fluorenes/therapeutic use , Malaria, Falciparum/drug therapy , Sesquiterpenes/therapeutic use , Adolescent , Adult , Artemether , Artesunate , Child , Child, Preschool , Drug Combinations , Female , Humans , Infant , Lumefantrine , Male , Mefloquine/therapeutic use , Middle Aged , Recurrence , Treatment Outcome
13.
Trans R Soc Trop Med Hyg ; 94(5): 537-44, 2000.
Article in English | MEDLINE | ID: mdl-11132385

ABSTRACT

Following a marked decline in the efficacy in vivo of mefloquine between 1990 and 1994, a combination of artesunate (4 mg/kg/d for 3 d) and mefloquine (25 mg/kg) has been used as first line treatment of uncomplicated falciparum malaria in camps for displaced persons located along the north-western border of Thailand. Antimalarial drug susceptibility of fresh isolates of Plasmodium falciparum from this population was evaluated using a radioisotope microdilution assay between 1995 and 1999. In total, 268 isolates were collected, of which 189 were from primary infections and 79 from recrudescent infections. The geometric mean 50% inhibitory concentration (IC50) values from primary infections were: dihydroartemisinin 1.2 ng/mL, artesunate 1.6 ng/mL, artemether 4.8 ng/mL, atovaquone 0.4 ng/mL, lumefantrine 32 ng/mL, chloroquine 149 ng/mL, quinine 354 ng/mL, mefloquine 27 ng/mL and halofantrine 4.1 ng/mL. A significant positive correlation was found between the susceptibility in vitro to artesunate and quinine (r = 0.43, P < 0.001), mefloquine (r = 0.46, P < 0.001), and halofantrine (r = 0.51, P < 0.001). These levels of resistance in vitro are among the highest reported and confirm continuing high level multidrug resistance in this area. Despite intensive use of the combination between 1995 and 1999 there has been a significant improvement in mefloquine sensitivity (P < 0.001) and artesunate sensitivity (P < 0.001). This supports observations in vivo that the combination of artesunate and mefloquine has reversed the previous decline in mefloquine sensitivity.


Subject(s)
Antimalarials/therapeutic use , Artemisinins , Malaria, Falciparum/drug therapy , Mefloquine/therapeutic use , Sesquiterpenes/therapeutic use , Adolescent , Adult , Aged , Animals , Artesunate , Child , Child, Preschool , Confounding Factors, Epidemiologic , Dose-Response Relationship, Drug , Drug Combinations , Female , Humans , Infant , Lethal Dose 50 , Malaria, Falciparum/epidemiology , Malaria, Falciparum/parasitology , Male , Microbial Sensitivity Tests , Middle Aged , Plasmodium falciparum/isolation & purification , Quality Control , Thailand/epidemiology
14.
Curr Opin Drug Discov Devel ; 3(4): 432-8, 2000 Jul.
Article in English | MEDLINE | ID: mdl-19649874

ABSTRACT

Over the course of the last three or four years, the need for increased throughput analytical methods in support of drug discovery operations has dramatically increased. Once a nicety, methods which can provide reliable quantitation of target analytes in biological fluids are now necessary to keep pace with biological screening. To date, the only successful approaches to direct high-speed quantitation of large numbers of diverse compounds are based on high-performance liquid chromatography/mass spectrometric (HPLC/MS/MS) techniques. Key challenges to this task include sample preparation, the automated development of methods and the rapid analysis of many samples. Accomplishing these tasks requires the use of generic methods, which can be applied across many structurally diverse compounds. In this review, the state-of-the-art in high-speed HPLC/MS/MS is reviewed with the aim of describing the most practical and effective approaches currently in use.

15.
Antimicrob Agents Chemother ; 43(12): 2943-9, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10582887

ABSTRACT

On the western border of Thailand, Plasmodium falciparum has become resistant to almost all antimalarial agents. The molecular basis of resistance in these parasite populations has not been well characterized. This study assessed genetic polymorphisms in the pfmdr1 gene in 54 parasites collected from the western border of Thailand to determine the relationship of pfmdr1 copy number and codon mutations with parasite sensitivities to mefloquine, chloroquine, halofantrine, quinine, and artesunate assessed in vitro. A point mutation at codon 86 (resulting in a change of Asn to Tyr) was associated with a significantly lower 50% inhibitory concentration (IC(50)) of mefloquine (median, 9 ng/ml versus 52.4 ng/ml; P = 0.003). Overall 35% of the isolates (19 of 54) had an increase in pfmdr1 copy number, and all 19 carried the wild-type allele at codon 86. Increased pfmdr1 copy number was associated with higher IC(50)s of mefloquine (P = 0.04) and artesunate (P = 0.005), independent of polymorphism at codon 86. The relationship between pfmdr1 and resistance to structurally distinct antimalarial agents confirms the presence of a true multidrug-resistant phenotype.


Subject(s)
ATP-Binding Cassette Transporters , Antimalarials/pharmacology , Drug Resistance, Multiple/genetics , Malaria, Falciparum/parasitology , Plasmodium falciparum/drug effects , Protozoan Proteins/genetics , Alleles , Animals , Antigens, Protozoan/genetics , Codon/genetics , DNA, Protozoan/analysis , DNA, Protozoan/genetics , Gene Dosage , Genetic Markers , Humans , Mefloquine/pharmacology , Phenotype , Polymorphism, Genetic/genetics , Reverse Transcriptase Polymerase Chain Reaction , Thailand
16.
Am J Trop Med Hyg ; 60(6): 936-42, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10403324

ABSTRACT

The new oral fixed combination artemether-lumefantrine (CGP 56697) has proved to be an effective and well-tolerated treatment of multi-drug resistant Plasmodium falciparum malaria, although cure rates using the four-dose regimen have been lower than with the currently recommended alternative of artesunate-mefloquine. Two six-dose schedules (total adult dose = 480 mg of artemether and 2,880 mg of lumefantrine) were therefore compared with the previously used four-dose regimen (320 mg of artemether and 1,920 mg of lumefantrine) in a double-blind trial involving 359 patients with uncomplicated multidrug-resistant falciparum malaria. There were no differences between the three treatment groups in parasite and fever clearance times, and reported adverse effects. The two six-dose regimens gave adjusted 28-day cure rates of 96.9% and 99.12%, respectively, compared with 83.3% for the four-dose regimen (P < 0.001). These six-dose regimens of artemether-lumefantrine provide a highly effective and very well-tolerated treatment for multidrug-resistant falciparum malaria.


Subject(s)
Antimalarials/therapeutic use , Artemisinins , Fluorenes/therapeutic use , Malaria, Falciparum/drug therapy , Plasmodium falciparum/drug effects , Sesquiterpenes/therapeutic use , Adolescent , Adult , Aged , Animals , Antimalarials/administration & dosage , Antimalarials/adverse effects , Antimalarials/standards , Artemether, Lumefantrine Drug Combination , Child , Child, Preschool , DNA, Protozoan/blood , Dose-Response Relationship, Drug , Double-Blind Method , Drug Combinations , Drug Resistance, Multiple , Ethanolamines , Female , Fluorenes/administration & dosage , Fluorenes/adverse effects , Fluorenes/standards , Humans , Male , Middle Aged , Recurrence , Sesquiterpenes/administration & dosage , Sesquiterpenes/adverse effects , Sesquiterpenes/standards , Thailand
17.
Rapid Commun Mass Spectrom ; 13(11): 1024-30, 1999.
Article in English | MEDLINE | ID: mdl-10368978

ABSTRACT

Cell-surface class I major histocompatibility complex (MHC) molecules present processed self- and nonself-peptides to thymus-derived (T) lymphocytes, allowing the intracellular compartment of cells to be sampled in order to detect infection. Since the class I MHC-peptide complex plays a critical role in cell-mediated immunity, it is important to obtain sequence information on the MHC-associated peptides unique to infected cells as a prelude to the development of vaccines. Here, we outline and test an alternative strategy for identifying the proteins that are processed through the MHC pathway. This new strategy eliminates the necessity of developing and maintaining cytotoxic T lymphocyte (CTL) lines for peptide identification. In this new approach genome sequences from the infecting agent are scanned for stretches of amino acids that match a particular MHC binding motif. Molecular masses from these putative MHC-binding peptide sequences are calculated and compared to those found for peptides isolated from pathogen-infected host cells using liquid chromatography/mass spectrometry (LC/MS). Peptides with masses matching those in the database are then analyzed by tandem mass spectrometry (MS/MS) to determine their identity. Using this approach we were able to confirm the processing and presentation of two Trypanosoma cruzi proteins by the MHC class I pathway. These data suggest that a rigorous approach employing two-dimensional separations in conjunction with MS/MS and bioinformatics is a feasible means of identifying pathogen gene products of immunological interest when a CTL assay is unavailable or unsuccessful.


Subject(s)
Genes, MHC Class I/genetics , Peptides/chemistry , Animals , Chagas Disease/metabolism , Chromatography, High Pressure Liquid , Flow Injection Analysis , Mass Spectrometry , Mice , Molecular Weight , Myocardium/chemistry , Trypanosoma cruzi
18.
Am J Trop Med Hyg ; 60(1): 14-21, 1999 Jan.
Article in English | MEDLINE | ID: mdl-9988316

ABSTRACT

Parasite genotyping by the polymerase chain reaction was used to distinguish recrudescent from newly acquired Plasmodium falciparum infections in a Karen population resident on the northwestern border of Thailand where malaria transmission is low (one infection/person/year). Plasmodium falciparum infections were genotyped for allelic variation in three polymorphic antigen loci, merozoite surface proteins-1 and -2 (MSP-1 and -2) and glutamaterich protein (GLURP), before and after antimalarial drug treatment. Population genotype frequencies were measured to provide the baseline information to calculate the probability of a new infection with a different or the same genotype to the initial pretreatment isolate. Overall, 38% of the infections detected following treatment had an identical genotype before and up to 121 days after treatment. These post-treatment genotypes were considered recrudescent because of the low (< 5%) probability of repeated occurrence by chance in the same patient. This approach allows studies of antimalarial drug treatment to be conducted in areas of low transmission since recrudescences can be distinguished confidently from newly acquired infections.


Subject(s)
Malaria, Falciparum/parasitology , Plasmodium falciparum/genetics , Alleles , Animals , Antigens, Protozoan/genetics , DNA, Protozoan/analysis , DNA, Protozoan/chemistry , Drug Resistance, Multiple , Gene Frequency , Genetic Markers , Genetic Variation , Genotype , Humans , Malaria, Falciparum/drug therapy , Malaria, Falciparum/epidemiology , Plasmodium falciparum/classification , Plasmodium falciparum/drug effects , Polymerase Chain Reaction , Polymorphism, Restriction Fragment Length , Recurrence , Thailand/epidemiology
19.
Trans R Soc Trop Med Hyg ; 93(6): 587-93, 1999.
Article in English | MEDLINE | ID: mdl-10717738

ABSTRACT

Genetic characterization of Plasmodium falciparum infections in north-western Thailand, a region of low transmission intensity (1 infection/person each year), has found a comparable number of parasite genotypes per infected person to regions with hyperendemic malaria. Clone multiplicity and parasite diversity were found to be homogeneous across 129 infected individuals comprising a range of age-groups (1.32 parasite genotypes; n = 98), patients (aged 2-16 years) with recrudescent infections (1.54; n = 13), and pregnant women (1.61; n = 18). Individuals belonging to groups with a high risk of infection, as deduced by clinical epidemiology, did not harbour a higher number of clones per infection, nor greater parasite diversity than low-risk groups. In fact, multiple genotype infections were as common in low-risk groups, suggesting that there is frequent transmission of polyclonal infections from a single inoculum, rather than superinfection. Such a polyclonal transmission system would enable generation of extensive parasite diversity by recombination, despite the low level of transmission. However, co-infection with P. vivax was associated with fewer P. falciparum genotypes per infection.


Subject(s)
Genetic Variation , Malaria, Falciparum/parasitology , Plasmodium falciparum/genetics , Adolescent , Adult , Animals , Child , Child, Preschool , Female , Genotype , Humans , Malaria, Falciparum/epidemiology , Malaria, Vivax/epidemiology , Malaria, Vivax/parasitology , Male , Plasmodium falciparum/classification , Plasmodium vivax/classification , Plasmodium vivax/genetics , Pregnancy , Pregnancy Complications, Parasitic/epidemiology , Pregnancy Complications, Parasitic/parasitology , Risk Factors , Thailand/epidemiology
20.
J Mass Spectrom ; 33(11): 1141-7, 1998 Nov.
Article in English | MEDLINE | ID: mdl-9835069

ABSTRACT

Matrix-assisted laser desorption/ionization (MALDI) probe surfaces derivatized with octadecanethiol (C18) can be used as hydrophobic solid-phase extraction devices to isolate and desalt biopolymers directly on the probe surface. Using quantitative MALDI, it was possible to determine the approximate amount of peptide that bound to C18 surfaces and thus to calculate a surface density. It was determined that the amount of peptide bound at the probe surface was independent of the analyte concentration in the immersion solution (from high- to sub-ng ml-1 concentrations), but rather was dependent on the immersion time of the surface as it was exposed to the analyte. The capacity of C18-derivatized probes to bind biopolymers in fixed amounts frees the analyst from the necessity for adjusting analyte concentration through multiple step procedures such as serial dilution or vacuum drying. This time savings result in an overall increase in the efficiency of the MALDI technique.


Subject(s)
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methods , Cytochrome c Group/chemistry , Half-Life , Hydrolysis , Indicators and Reagents , Renin/metabolism , Surface Properties , Trypsin
SELECTION OF CITATIONS
SEARCH DETAIL
...